Enliven (ELVN) Therapeutics announced that it has commenced an underwritten public offering of $200M of shares of its common stock and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase shares of Enliven’s common stock. All of the shares of common stock and pre-funded warrants are being offered by Enliven. Jefferies, Goldman Sachs & Co., TD Cowen and Mizuho are acting as joint book-running managers for the proposed offering. LifeSci Capital is acting as lead manager for the proposed offering.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELVN:
- Enliven announces updated data from ELVN-001 trial
- Enliven Therapeutics’ ELVN-001: Promising CML Treatment with Strong Safety Profile and Upcoming Phase 1b Trial Insights
- Enliven Therapeutics: Buy Rating Backed by Promising ELVN-001 Developments in CML Treatment
- Promising Potential of Enliven Therapeutics’ ELVN-001 Drives Buy Rating
- Enliven Therapeutics’ ELVN-001: Promising Efficacy and Safety in Late Line CML Market